December 16, 2021
1 min read
Save
Aramis Biosciences launches to target dry eye disease treatment gap
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Aramis Biosciences has launched following the completion of Series A financing totaling $10.5 million, according to a press release.
The company’s lead candidate, A197, is a first-in-class topical immunomodulatory agent for the treatment of dry eye disease. A197 is licensed from Dompé.
“Aramis Biosciences was founded to address this treatment gap with A197, a new molecular entity promising a rapid onset of action, a durable, disease-modifying effect and a clean tolerability profile,” Reza Dana, MD, MPH, MSc, scientific co-founder of Aramis Biosciences, said in the release.
The funding will support Aramis’ pipeline through a phase 2 clinical proof of concept trial for A197.
Published by:
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.